| 4E-BP1 | Eukaryotic translation initiation factor 4E-binding protein 1 |
| 53BP1 | p53-binding protein 1 |
| A2aR | Adenosine A2a receptor |
| AKT | Protein kinase B |
| ANXA6 | Annexin A6 |
| APLNR | Apelin receptor |
| ATG5 | Autophagy-related gene 5 |
| ATM | Ataxia telangiectasia mutated |
| ATR | Ataxia telangiectasia and Rad3-related |
| BABAM1 | BRISC and BRCA1-A complex member 1 |
| BAD | Bcl-2-associated agonist of cell death |
| Bax | Bcl-2-associated X protein |
| Bcl-2 | B-cell lymphoma 2 |
| C2orf40 | Chromosome 2 open reading frame 40 |
| CALD1 | Caldesmon 1 |
| CD44 | Cluster of differentiation 44 |
| CDK1 | Cyclin-dependent kinase 1 |
| Chk2 | Checkpoint kinase 2 |
| c-Jun | Cellular Jun proto-oncogene |
| CRC | Colorectal cancer |
| CSCs | Cancer stem cells |
| DDRs | DNA damage responses |
| DEPTOR | DEP domain-containing mTOR-interacting protein |
| DNA-PKcs | DNA-dependent protein kinase catalytic subunit |
| DSBs | DNA double-strand breaks |
| EMT | Epithelial–mesenchymal transition |
| EpCAM | Epithelial cell adhesion molecule |
| ESCC | Esophageal squamous cell carcinoma |
| FA | Fanconi anemia |
| FAM135B | Family with sequence similarity 135, member B |
| FANCD2 | Fanconi anemia complementation group D2 |
| FOXO1 | Forkhead Box O1 |
| GBM | Glioblastoma |
| Glut-1 | Glucose transporter 1 |
| GSK-3β | Glycogen synthase kinase 3 beta |
| GβL | G-protein β-subunit-like protein |
| HIF-1α | Hypoxia-inducible factor 1-alpha |
| HNSCC | Head and neck squamous cell carcinoma |
| HR | Homologous recombination |
| Hsp90 | Heat shock protein 90 |
| IMRT | Intensity-modulated radiotherapy |
| LC3-II | Microtubule-associated protein 1 light chain 3 II |
| MDSC | Myeloid-derived suppressor cell |
| mLST8 | Mammalian lethal with SEC13 protein 8 |
| MRN | MRE11-RAD50-NBS1 complex |
| mTOR | Mammalian target of rapamycin |
| Nbs1 | Nijmegen breakage syndrome 1 protein |
| NEDD8 | Neural precursor cell expressed, developmentally downregulated 8 |
| NHEJ | Non-homologous end joining |
| NPC | Nasopharyngeal carcinoma |
| NSCLC | Non-small-cell lung cancer |
| OCT-4 | Octamer-binding transcription factor 4 |
| OS | Overall survival |
| P62 | Sequestosome-1 |
| PARP1 | Poly(ADP-ribose)polymerase 1 |
| PCNA | Proliferating cell nuclear antigen |
| PDK1 | Phosphoinositide-dependent protein kinase 1 |
| PFS | Progression-free survival |
| PI3K | Phosphatidylinositol 3-Kinase |
| PRAS40 | Proline-rich AKT substrate of 40 kDa |
| PTEN | Phosphatase and tensin homolog |
| RAPTOR | Regulatory-associated protein of mTOR |
| Rad51 | RAD51 recombinase |
| Rb | Retinoblastoma protein |
| RCC | Renal cell carcinoma |
| RFC1 | Replication factor C subunit 1 |
| RNR | Phosphorylates ribonucleotide reductase |
| ROS | Reactive oxygen species |
| S2056 | Serine 2056 |
| S6K | Sibosomal protein S6 kinase |
| SBRT | Stereotactic body radiotherapy |
| SCLC | Small-cell lung cancer |
| SIN1 | Stress-activated protein kinase-interacting protein 1 |
| SIRT6 | Sirtuin 6 |
| SLC7A5 | Solute carrier family 7 member A5 |
| SMA | Smooth muscle actin |
| SOX2 | SRY-box transcription factor 2 |
| SSBs | Single-strand breaks |
| TAMs | Tumor-associated macrophages |
| TEH | Tenacissoside H |
| VEGF | Vascular endothelial growth factor |